EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

Toremifene, an Alternative Adjuvant Endocrine Therapy, Is Better Than Tamoxifen in Breast Cancer Patients with CYP2D6*10 Mutant Genotypes

Xin Li, Zehao Li, Lin Li, Tong Liu, Cheng Qian, Yanlv Ren, Zhigao Li, Kejin Chen, Dongchen Ji, Ming Zhang, Jinsong Wang

Cancer Research and Treatment · 2024

DOI: 10.4143/crt.2023.652 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Research and Treatment, 2024. Verfasst von Xin Li und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast Surgery, Harbin Medical University Cancer Hospital, Harbin, China. Hauptthemen laut MEDLINE: Tamoxifen, Breast Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Tamoxifen showed individual differences in efficacy under different CYP2D6*10 genotypes. Our study evaluated the prognosis of tamoxifen or toremifene in hormone receptor (HR)–positive breast cancer patients under different genotypes.Materials and Methods CYP2D6*10 genotypes of HR-positive breast cancer patients were determined by Sanger sequencing, and all the patients were divided into tamoxifen group or toremifene group.

Results

A total of 268 patients with HR-positive breast cancer were studied. The median follow-up time was 72.0 months (range, 5.0 to 88.0 months). Of these, 88 (32.9%), 114 (42.5%), and 66 (24.6%) patients had C/C, C/T, and T/T genotypes, respectively. Among patients who received tamoxifen (n=176), the 5-year disease-free survival (DFS) rate in patients with C/C and C/T genotype was better than that in patients with T/T genotype, and the difference was statistically significant (p < 0.001 and p=0.030, respectively). In patients receiving toremifene, CYP2D6*10 genotype was not significantly associated with DFS (p=0.325). Regardless of genotypes, the 5-year DFS rate was higher in patients treated with toremifene than in patients with tamoxifen (91.3% vs. 80.0%, p=0.011). Compared with tamoxifen, toremifene remained an independent prognostic marker of DFS in multivariate analysis (hazard ratio, 0.422; p=0.021). For all the 180 patients with CYP2D6*10 C/T and T/T genotypes, the 5-year DFS rate was significantly higher in the toremifene group than in the tamoxifen group (90.8% vs. 70.1%, p=0.003).

Conclusion

Toremifene may be an alternative adjuvant endocrine therapy for patients with CYP2D6*10 mutant genotypes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TamoxifenBreast NeoplasmsHumansFemaleToremifeneCytochrome P-450 CYP2D6Antineoplastic Agents, HormonalChemotherapy, AdjuvantGenotype

Stichwörter der Autor:innen

Breast neoplasmsCYP2D6*10 polymorphismTamoxifenToremifene

Substanzen

TamoxifenToremifeneCytochrome P-450 CYP2D6Antineoplastic Agents, Hormonal

Autor:innen und Institutionen

  • Department of Breast Surgery, Harbin Medical University Cancer Hospital, Harbin, China.
  • Department of Clinical Medicine, Jiamusi University, Jiamusi, Heilongjiang, China.
  • Depatment of Thyroid and Breast Surgery, Ningbo Medical Center, Li Huili Hospital, Ningbo, China.

Zitieren

APA

Li, X., Li, Z., Li, L., Liu, T., Qian, C., Ren, Y., Li, Z., Chen, K., Ji, D., Zhang, M., & Wang, J. (2024). Toremifene, an Alternative Adjuvant Endocrine Therapy, Is Better Than Tamoxifen in Breast Cancer Patients with CYP2D6*10 Mutant Genotypes. Cancer Research and Treatment. https://doi.org/10.4143/crt.2023.652

Vancouver

Li X, Li Z, Li L, Liu T, Qian C, Ren Y, et al. Toremifene, an Alternative Adjuvant Endocrine Therapy, Is Better Than Tamoxifen in Breast Cancer Patients with CYP2D6*10 Mutant Genotypes. Cancer Research and Treatment. 2024. doi:10.4143/crt.2023.652

BibTeX
@article{Li2024,
  author = {Li, Xin and Li, Zehao and Li, Lin and Liu, Tong and Qian, Cheng and Ren, Yanlv and Li, Zhigao and Chen, Kejin and Ji, Dongchen and Zhang, Ming and Wang, Jinsong},
  title = {Toremifene, an Alternative Adjuvant Endocrine Therapy, Is Better Than Tamoxifen in Breast Cancer Patients with CYP2D6*10 Mutant Genotypes},
  journal = {Cancer Research and Treatment},
  year = {2024},
  doi = {10.4143/crt.2023.652}
}
Kostenlos starten →